StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO)

Stock analysts at StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report released on Thursday. The brokerage set a “hold” rating on the medical research company’s stock.

Several other research analysts have also recently commented on CTSO. D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Cytosorbents in a research report on Monday, January 13th. HC Wainwright reissued a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a research report on Monday, November 11th. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $4.67.

Cytosorbents Stock Up 2.2 %

CTSO stock opened at $1.01 on Thursday. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The stock has a market capitalization of $55.23 million, a P/E ratio of -2.81 and a beta of 0.61. The business has a 50-day moving average of $0.96 and a 200-day moving average of $1.04. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $1.59.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Thursday, November 7th. The medical research company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.03). The firm had revenue of $9.39 million for the quarter, compared to analyst estimates of $10.14 million. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. During the same period in the prior year, the company earned ($0.21) earnings per share. On average, sell-side analysts anticipate that Cytosorbents will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of Cytosorbents

Institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC raised its stake in Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after buying an additional 32,415 shares during the period. Sargent Investment Group LLC raised its stake in Cytosorbents by 13.4% in the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after buying an additional 192,747 shares during the period. Atomi Financial Group Inc. bought a new stake in Cytosorbents in the third quarter valued at approximately $51,000. Finally, Skylands Capital LLC raised its stake in Cytosorbents by 1.0% in the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after buying an additional 26,195 shares during the period. Institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.